سعر ميوكوفار 120 مل شراب 15 مجم/5 مل 2025

Mucofar ambroxol 15 mg/5 ml syrup, 120 ml bottle (Pharco); mucolytic.

• Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with disturbed mucus formation and transport.Population: Adults and childrenFachinfo-Service (Rote Liste Service GmbH)

• Common: taste disturbance, nausea, numbness of the mouth and throat. Uncommon: vomiting, diarrhoea, dyspepsia, abdominal pain, dry mouth, fever, mucosal reactions. Rare: hypersensitivity reactions, rash, urticaria, dry throat. Not known: anaphylactic reactions including shock, angioedema, pruritus, severe skin reactions.International label, same formulation · Fachinfo-Service (Rote Liste Service GmbH)

• Hypersensitivity to ambroxol or to any excipient.International label, same formulation · Fachinfo-Service (Rote Liste Service GmbH)

• Children under 2 years: use only on medical advice.International label, same formulation · Fachinfo-Service (Rote Liste Service GmbH)
• Severe skin reactions (erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis, acute generalised exanthematous pustulosis) have been reported with ambroxol; stop treatment immediately and seek medical advice if a progressive rash (sometimes with blisters or mucosal lesions) appears.International label, same formulation · Fachinfo-Service (Rote Liste Service GmbH)
• Use with caution in impaired bronchial motility and large secretion volumes (e.g. rare malignant ciliary syndrome) because secretions may accumulate.International label, same formulation · Fachinfo-Service (Rote Liste Service GmbH)

• Antitussives (cough suppressants)Combined use with antitussives can cause dangerous accumulation of secretions because the cough reflex is reduced; combine only after careful benefit-risk assessment.Fachinfo-Service (Rote Liste Service GmbH)

• Ambroxol crosses the placenta; non-clinical studies showed no direct or indirect harm, and extensive clinical experience after week 28 showed no harmful effect on the fetus; usual precautions apply.International label, same formulation · Fachinfo-Service (Rote Liste Service GmbH)
• Ambroxol passes into breast milk in animal studies; use during breastfeeding is not recommended.International label, same formulation · Fachinfo-Service (Rote Liste Service GmbH)

• Ambroxol: Increases the serous fraction of bronchial secretions, stimulates surfactant production by type II pneumocytes and Clara cells and stimulates ciliary activity, lowering mucus viscosity and improving mucociliary clearance.